Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Acute liver failure in adults: Management and prognosis

Topic Outline

GRAPHICS

CALCULATORS

INTRODUCTION

Acute liver failure refers to the development of severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio [INR] of ≥1.5) in a patient without cirrhosis or preexisting liver disease [1,2]. While the time course that differentiates acute liver failure from chronic liver failure varies between reports, a commonly used cut-off is an illness duration of <26 weeks.

Acute liver failure may also be diagnosed in patients with previously undiagnosed Wilson disease, vertically-acquired hepatitis B virus, or autoimmune hepatitis, in whom underlying cirrhosis may be present, provided the disease has been recognized for <26 weeks. On the other hand, patients with acute severe alcoholic hepatitis, even if recognized for <26 weeks, are considered to have acute-on-chronic liver failure since most have a long history of heavy drinking. The approach to such patients is discussed elsewhere. (See "Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis" and "Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis".)

Acute liver failure has also been referred to as fulminant hepatic failure, acute hepatic necrosis, fulminant hepatic necrosis, and fulminant hepatitis. Untreated, the prognosis is poor, so timely recognition and management of patients with acute liver failure is crucial [3]. Whenever possible, patients with acute liver failure should be managed in an intensive care unit at a facility capable of performing liver transplantation.

This topic will review and the management and prognosis of acute liver failure in adults. The etiology, clinical manifestations, and diagnosis of patients with acute liver failure are discussed separately. (See "Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis".)

The discussion that follows is consistent with the 2011 The American Association for the Study of Liver Diseases (AASLD) guideline for the management of acute liver failure [1,2].

                                                   

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Feb 18, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012; 55:965.
  2. http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf (Accessed on August 08, 2012).
  3. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology 2008; 47:1401.
  4. Lee WM. Acute liver failure. N Engl J Med 1993; 329:1862.
  5. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol 2009; 6:542.
  6. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int 2003; 23:71.
  7. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36:395.
  8. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137:856.
  9. Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975; 16:617.
  10. Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis 2009; 13:95.
  11. Shami VM, Hespenheide EE, Macik BG, et al. Recombinant activated factor VII in fulminant liver failure: Complete but transient correction of the coagulopathy (abstract). Hepatology 2000; 32:397A.
  12. Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S101.
  13. Négrier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S19.
  14. Kaliciński P, Kamiński A, Drewniak T, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31:378.
  15. Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 2001; 86:1125.
  16. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138.
  17. Shami VM, Macik BG, Hespenheide EE, et al. Recombinant activated factor VII is superior to plasma alone in correcting the coagulopathy of fulminant hepatic failure (abstract). Hepatology 2001; 34:237A.
  18. Mas A, Rodés J. Fulminant hepatic failure. Lancet 1997; 349:1081.
  19. Rolando N, Gimson A, Wade J, et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993; 17:196.
  20. Rolando N, Harvey F, Brahm J, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991; 12:1.
  21. Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns 1997; 23:313.
  22. Muñoz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Dis 1993; 13:395.
  23. Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology 2014; 59:612.
  24. Woolf GM, Redeker AG. Treatment of fulminant hepatic failure with insulin and glucagon. A randomized, controlled trial. Dig Dis Sci 1991; 36:92.
  25. O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94:1186.
  26. Sinclair SB, Levy GA. Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report. Dig Dis Sci 1991; 36:791.
  27. Sheiner P, Sinclair S, Greig P, et al. A randomized control trial of prostaglandin E2 in the treatment of fulminant hepatic failure (abstract). Hepatology 1992; 16:88A.
  28. Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20:1058.
  29. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557.
  30. Prescott LF. Treatment of severe acetaminophen poisoning with intravenous acetylcysteine. Arch Intern Med 1981; 141:386.
  31. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767.
  32. Belongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008; 25:1.
  33. Roussos A, Koilakou S, Kalafatas I, et al. Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta Gastroenterol Belg 2008; 71:30.
  34. Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47:1293.
  35. Dao DY, Seremba E, Ajmera V, et al. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci 2012; 57:1349.
  36. O'Grady JG, Portmann B, Williams R. Fulminant hepatic failure. In: Diseases of the Liver, Schiff L, Schiff R (Eds), JB Lippincott, Philadelphia 1993.
  37. Caraceni P, Van Thiel DH. Acute liver failure. Lancet 1995; 345:163.
  38. Baquerizo A, Anselmo D, Shackleton C, et al. Phosphorus ans an early predictive factor in patients with acute liver failure. Transplantation 2003; 75:2007.
  39. Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341:157.
  40. Kaur S, Kumar P, Kumar V, et al. Etiology and prognostic factors of acute liver failure in children. Indian Pediatr 2013; 50:677.
  41. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337:473.
  42. Alba L, Hay JE, Lee WM. Lactulose therapy in acute liver failure. J Hepatol 2002; 36:33A.
  43. Williams R, Gimson AE. Intensive liver care and management of acute hepatic failure. Dig Dis Sci 1991; 36:820.
  44. Ware AJ, D'Agostino AN, Combes B. Cerebral edema: a major complication of massive hepatic necrosis. Gastroenterology 1971; 61:877.
  45. Stravitz RT. Critical management decisions in patients with acute liver failure. Chest 2008; 134:1092.
  46. McCashland TM, Shaw BW Jr, Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis 1996; 16:427.
  47. Keays RT, Alexander GJ, Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993; 18:205.
  48. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 11:1581.
  49. Manno EM. Transcranial Doppler ultrasonography in the neurocritical care unit. Crit Care Clin 1997; 13:79.
  50. Edouard AR, Vanhille E, Le Moigno S, et al. Non-invasive assessment of cerebral perfusion pressure in brain injured patients with moderate intracranial hypertension. Br J Anaesth 2005; 94:216.
  51. Abdo A, López O, Fernández A, et al. Transcranial Doppler sonography in fulminant hepatic failure. Transplant Proc 2003; 35:1859.
  52. Aggarwal S, Brooks DM, Kang Y, et al. Noninvasive monitoring of cerebral perfusion pressure in patients with acute liver failure using transcranial doppler ultrasonography. Liver Transpl 2008; 14:1048.
  53. Durward QJ, Amacher AL, Del Maestro RF, Sibbald WJ. Cerebral and cardiovascular responses to changes in head elevation in patients with intracranial hypertension. J Neurosurg 1983; 59:938.
  54. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004; 39:464.
  55. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240.
  56. Canalese J, Gimson AE, Davis C, et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982; 23:625.
  57. Nath F, Galbraith S. The effect of mannitol on cerebral white matter water content. J Neurosurg 1986; 65:41.
  58. Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994; 19:1407.
  59. Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996; 16:379.
  60. Ede RJ, Gimson AE, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986; 2:43.
  61. Hanid MA, Davies M, Mellon PJ, et al. Clinical monitoring of intracranial pressure in fulminant hepatic failure. Gut 1980; 21:866.
  62. Rakela J, Mosley JW, Edwards VM, et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci 1991; 36:1223.
  63. Traber P, DalCanto M, Ganger D, Blei AT. Effect of body temperature on brain edema and encephalopathy in the rat after hepatic devascularization. Gastroenterology 1989; 96:885.
  64. Dmello D, Cruz-Flores S, Matuschak GM. Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. Intensive Care Med 2010; 36:210.
  65. Jalan R, O Damink SW, Deutz NE, et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999; 354:1164.
  66. Jalan R, Olde Damink SW, Deutz NE, et al. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004; 127:1338.
  67. Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med 2009; 37:S258.
  68. Clemmesen JO, Hansen BA, Larsen FS. Indomethacin normalizes intracranial pressure in acute liver failure: a twenty-three-year-old woman treated with indomethacin. Hepatology 1997; 26:1423.
  69. Tofteng F, Larsen FS. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2004; 24:798.
  70. Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology 2000; 32:536.
  71. Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure--a controlled clinical trial. J Hepatol 2004; 41:89.
  72. O'Grady JG, Williams R. Acute liver failure. In: Gastrointestinal emergencies, Gilmore IT, Shields R (Eds), WB Saunders, Eastbourne 1992. p.104.
  73. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.
  74. Jain S, Pendyala P, Varma S, et al. Effect of renal dysfunction in fulminant hepatic failure. Trop Gastroenterol 2000; 21:118.
  75. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21:328.
  76. Lidofsky SD. Liver transplantation for fulminant hepatic failure. Gastroenterol Clin North Am 1993; 22:257.
  77. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947.
  78. Miyake Y, Sakaguchi K, Iwasaki Y, et al. New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure. Transplantation 2005; 80:930.
  79. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36:659.
  80. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29:648.
  81. Kumar R, Sharma H, Prakash S, et al. Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. Clin Gastroenterol Hepatol 2012; 10:925.
  82. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41:26.
  83. Hanau C, Munoz SJ, Rubin R. Histopathological heterogeneity in fulminant hepatic failure. Hepatology 1995; 21:345.
  84. Dhiman RK, Seth AK, Jain S, et al. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 1998; 43:1311.
  85. Huo TI, Wu JC, Sheng WY, et al. Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. J Gastroenterol Hepatol 1996; 11:560.
  86. Takahashi Y, Kumada H, Shimizu M, et al. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994; 19:1065.
  87. Lake JR, Sussman NL. Determining prognosis in patients with fulminant hepatic failure: when you absolutely, positively have to know the answer. Hepatology 1995; 21:879.
  88. Dhiman RK, Jain S, Maheshwari U, et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 2007; 13:814.
  89. Yantorno SE, Kremers WK, Ruf AE, et al. MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 2007; 13:822.
  90. Craig DG, Zafar S, Reid TW, et al. The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose. Aliment Pharmacol Ther 2012; 35:1408.
  91. Craig DG, Reid TW, Wright EC, et al. The sequential organ failure assessment (SOFA) score is prognostically superior to the model for end-stage liver disease (MELD) and MELD variants following paracetamol (acetaminophen) overdose. Aliment Pharmacol Ther 2012; 35:705.
  92. Kumar R, Sharma H, Goyal R, et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut 2012; 61:1068.
  93. Pauwels A, Mostefa-Kara N, Florent C, Lévy VG. Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria. J Hepatol 1993; 17:124.
  94. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6:648.
  95. Rutherford A, King LY, Hynan LS, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 2012; 143:1237.
  96. Craig DG, Ford AC, Hayes PC, Simpson KJ. Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment Pharmacol Ther 2010; 31:1064.
  97. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997; 26:62.
  98. McPhail MJ, Wendon JA, Bernal W. Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol 2010; 53:492.
  99. Parkash O, Mumtaz K, Hamid S, et al. MELD score: utility and comparison with King's College criteria in non-acetaminophen acute liver failure. J Coll Physicians Surg Pak 2012; 22:492.
  100. Katoonizadeh A, Decaestecker J, Wilmer A, et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 2007; 27:329.
  101. Zaman MB, Hoti E, Qasim A, et al. MELD score as a prognostic model for listing acute liver failure patients for liver transplantation. Transplant Proc 2006; 38:2097.
  102. Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45:789.
  103. Nyberg SL, Misra SP. Hepatocyte liver-assist systems--a clinical update. Mayo Clin Proc 1998; 73:765.
  104. Stockmann HB, Hiemstra CA, Marquet RL, IJzermans JN. Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg 2000; 231:460.
  105. Pless G, Sauer IM. Bioartificial liver: current status. Transplant Proc 2005; 37:3893.
  106. Xu X, Liu X, Ling Q, et al. Artificial liver support system combined with liver transplantation in the treatment of patients with acute-on-chronic liver failure. PLoS One 2013; 8:e58738.
  107. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289:217.
  108. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004; :CD003628.
  109. Lodge JP, Dasgupta D, Prasad KR, et al. Emergency subtotal hepatectomy: a new concept for acetaminophen-induced acute liver failure: temporary hepatic support by auxiliary orthotopic liver transplantation enables long-term success. Ann Surg 2008; 247:238.
  110. Ringers J, Dubbeld J, Baranski AG, et al. Reuse of auxiliary liver grafts in second recipients with chronic liver disease. Am J Transplant 2007; 7:2615.
  111. Starzl TE, Murase N, Thomson AW, et al. Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Transplant Proc 1999; 31:1806.
  112. Hara H, Gridelli B, Lin YJ, et al. Liver xenografts for the treatment of acute liver failure: clinical and experimental experience and remaining immunologic barriers. Liver Transpl 2008; 14:425.
  113. Bonavita AG, Quaresma K, Cotta-de-Almeida V, et al. Hepatocyte xenotransplantation for treating liver disease. Xenotransplantation 2010; 17:181.
  114. Kim K, Schuetz C, Elias N, et al. Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons. Xenotransplantation 2012; 19:256.
  115. Ekser B, Lin CC, Long C, et al. Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation. Transpl Int 2012; 25:882.
  116. Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142:505.
  117. Brown RS Jr, Russo MW, Lai M, et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348:818.
  118. Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995; 222:109.